GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
GAiT Directors Jihwan Song and Anna Falk and @NYSCF Representative Jeff Wallerstein discuss a global haplobank network for clinical-grade iPS cells at #ISSCR2022
GAiT will speak at the iPSC Manufacturing Summit in Boston 26th-28th July 2022
iPSC Manufacturing Summit 2022
Join us in Boston for the iPSC Manufacturing Summit, the only forum dedicated to optimizing the scalable manufacture...
GAiT speaking at #VLGeneCell conference 9th June 2022 in Berlin
GAiT will speak at ATMP Sweden's World Tour Event next week (Wednesday 8th June 2022). Register now at https://atmpsweden.se/events/atmp-world-tour-2022/
GAiT will speak at the 4th Gene and Cell Therapy Conference and Exhibition in Berlin 8-9th June 2022
4th Gene and Cell Therapy: Quality Developments, Manufacturing & Commercialization Summit | Vonlanthen
4th Gene and Cell Therapy: Quality Developments, Manufacturing & Commercialization Summit on 8-9 June 2022. #VLGeneCell ...